NFNoah M. Feder

Noah M. Feder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noah M. Feder has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Abigail Balsan

    Department of Orthopaedic Surgery, UPMC Freddie Fu Sports Medicine Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    1 shared publication
  • Adam Popchak

    Department of Orthopaedic Surgery, UPMC Freddie Fu Sports Medicine Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    1 shared publication
  • Albert Lin

    Department of Orthopaedic Surgery, UPMC Freddie Fu Sports Medicine Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    1 shared publication
  • Ali Amin

    Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA

    1 shared publication
  • Amin Karimi

    Department of Orthopaedic Surgery, UPMC Freddie Fu Sports Medicine Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    1 shared publication
  • Amr Kaadan

    Department of Orthopedic Surgery, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA

    1 shared publication

Latest Publications

  • Open Access

    Comparison of complication rates and outcomes for various surgical techniques for the repair of acute distal triceps ruptures

    by Nicholas F. Aloi, Jacob N. Weinberg, Noah M. Feder, Hannah L. Tetreault, Krishna P. Nayak, John R. Fowler

  • Open Access

    Preoperative Instability Episodes as a Predictor of Recurrence After Arthroscopic Bankart Repair

    by Ryan T. Lin, Ryan Gilbert, Sahil Dadoo, Amin Karimi, Noah Feder, Abigail Balsan, Ehab M. Nazzal, Shaquille Charles, Jonathan D. Hughes, Adam Popchak, et al.

    Background: Previous literature has demonstrated that an increased number of preoperative anterior shoulder instability episodes is associated with recurrent anterior shoulder instability after arthroscopic Bankart repair (ABR). However, a threshold for the number of preoperative instability episodes that increases the risk of recurrent anterior shoulder instability is not well established. Purpose: To establish a threshold value for the number of preoperative instability episodes that predicts recurrent anterior shoulder instability after ABR and to compare glenoid bone loss, the Hill-Sachs interval, and the distance to dislocation between patients who have surpassed the threshold and those who have not. Study Design: Retrospective cohort study; Level of evidence, 3. Methods: This retrospective review included consecutive patients with “on-track” Hill-Sachs lesions who underwent primary ABR for anterior shoulder instability at a single institution between 2007 and 2019. Patients with an unknown number of preoperative instability episodes, >20% glenoid bone loss, 40 or P < .050. Results: A total of 151 patients (mean age, 20 ± 5 years; mean follow-up, 6.0 ± 3.1 years) were included, of whom 28 (19%) experienced recurrent anterior shoulder instability. Multiple thresholds showed increased odds of recurrent anterior shoulder instability: ≥2 preoperative anterior shoulder instability events (odds ratio [OR], 9.70 [95% CI, 2.63-35.70]; P = .001), ≥3 events (OR, 3.47 [95% CI, 1.37-8.80]; P = .009), and ≥4 events (OR, 3.08 [95% CI, 1.17-8.08]; P = .023). Receiver operating characteristic analysis revealed that ≥2 preoperative anterior shoulder instability events was the strongest predictor of recurrent anterior shoulder instability (area under the curve = 0.72). Conclusion: A threshold of ≥2 preoperative anterior shoulder instability episodes best predicted recurrent anterior shoulder instability after ABR. Stratification beyond 1 versus ≥2 preoperative anterior shoulder instability episodes did not increase predictive ability. This finding may help surgeons to counsel patients and consider earlier surgical stabilization in those who have sustained anterior shoulder instability episodes.


  • Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 2021

    by Daniel M. Hartung, Nico Gabriel, Walid F. Gellad, Teresa Cameron, Noah M. Feder, Inmaculada Hernandez

    The objective of this study was to evaluate changes in net and list prices of branded multiple sclerosis (MS) disease-modifying therapies (DMTs) between 2013 and 2021. Using several pharmaceutical pricing and utilization data sources, we estimated list and net (after rebates and discounts) prices for branded monoclonal antibody (MAb) and oral DMTs. We calculated the inflation-adjusted list and net prices for each DMT, the manufacturer discount as a percentage of list price, the average annual change (AAC) in prices, and the cumulative change in list price offset by discounts. From 2013 to 2021, oral DMT list prices increased from $73,924 to $104,372 (5.3% AAC) while net prices rose from $69,187 to $82,181 (1.5% AAC) because of increasing manufacturer discounts (6.4%-21.2%). From 2014 to 2021, MAb DMT list prices increased from $70,320 to $92,109 (4.1% AAC), with net prices rising from $55,109 to $79,396 (3.0% AAC). Discounts offset 51%-86% of cumulative list price increases for oral DMTs (fingolimod, teriflunomide) vs 0%-35% for MAb DMTs. The divergent net pricing trends between oral and MAb DMTs may reflect increasing brand and generic competition among oral DMTs and a lack of biosimilar options among MAb DMTs.


  • Open Access

    Price transparency compliance and variation for proton therapy in the United States

    by Kasey R. Cargill, Noah M. Feder, Tyler Wilhite, Walid F. Gellad, Heath D. Skinner, Yvonne M. Mowery, Christopher T. Wilke

  • Open Access

    The GNAS Gene: Fibrous Dysplasia, McCune–Albright Syndrome, and Skeletal Structure and Function

    by Jake Louis Littman, Wentian Yang, Noah Feder, Amr Kaadan, Ali Amin, Roy K. Aaron

    McCune–Albright Syndrome (MAS) is a rare mosaic disorder caused by somatic activating mutations of the GNAS gene, resulting in constitutive Gsα signaling and a broad spectrum of clinical phenotypes. The syndrome typically presents with fibrous dysplasia (FD) of bone, café-au-lait macules, and endocrinopathies such as gonadotropin-independent precocious puberty, hyperthyroidism, and/or growth hormone excess. FD, which characterizes the skeletal phenotype, results in the replacement of normal bone with disorganized fibro-osseous tissue, often leading to pain, deformities, and increased risk of fractures. This review discusses the following: 1. The molecular biology of the GNAS locus and its relation to the pathophysiology of FD/MAS; 2. The skeletal manifestations of FD/MAS; 3. Bone biomechanics and organizational skeletal aberrations observed in FD/MAS; and 4. Current and future therapeutic strategies for patients with FD/MAS. While there is much current literature available regarding FD/MAS, this review specifically aims to outline core understandings and summarize some of the latest investigations into the genotypic and phenotypic foundations of the disorders, while shedding new light on the biomechanical aberrations observed in skeletal structure within them and comparing them to those observed in related disease processes such as osteoporosis and Paget’s disease.